The mR­NA era is here. MPM be­lieves the fu­ture be­longs to oR­NA — and Big Phar­ma wants a seat at the ta­ble

If the ul­tra-fast clin­i­cal de­vel­op­ment of Covid-19 vac­cines opened the world’s eyes to the promis­es of mes­sen­ger RNA, the sub­se­quent de­lays in sup­ply of­fered a crash course on the ul­tra-com­plex process of pro­duc­ing them. Even be­fore the for­mu­la­tion and fill-fin­ish steps, mR­NA is the pre­cious end prod­uct from an ar­du­ous jour­ney in­volv­ing en­zyme-aid­ed tran­scrip­tion, mod­i­fi­ca­tion and pu­rifi­ca­tion.

For Bris­tol My­ers Squibb, No­var­tis In­sti­tutes for Bio­med­ical Re­search, Gilead’s Kite and Astel­las, it’s time to re­think the way ther­a­peu­tic RNA is en­gi­neered.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER